Clinical Trial

A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to assess preliminary efficacy, determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-18; most recent amendment 2026-07-06.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT07086105
Lead Sponsor Adze Biotechnology Australia Pty Ltd
Conditions Metastatic Melanoma
Enrollment 30 participants
Start Date 2025-10-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-08